Navigation Links
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Date:4/23/2009

3 through 17 years receiving PEGINTRON/REBETOL combination therapy, weight loss and growth inhibition were common.

Patients receiving PEGINTRON and REBETOL as retreatment after failing a previous interferon combination regimen reported adverse reactions similar to those previously associated with this regimen during clinical trials of treatment-naive patients.

Please see important full U.S. prescribing information and the Medication Guide for PEGINTRON at www.schering-plough.com.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential market for PEGINTRON and REBETOL. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including uncertainties in the regulatory process, among other uncertainties. For further details
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... (OFT) approval condition to the announced tender offer for all of ... As a result of the waiver, the transaction is no longer ... offer on January 24, 2014 following the currently scheduled expiration time, ...
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
(Date:7/10/2014)... (PRWEB) July 10, 2014 Register to ... DataSite recently streamed the live webinar ‘Capitalizing on the ... from a group of several M&A experts in the ... the broader energy transaction marketplace. These experts shared their ... the deal market in this sector has been revitalized. ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 ... and believes that having family close by during ... difference in whether or not the process is ... of its website at http://www.bestdrugrehabilitation.com/success-stories/ . , ... and video testimonials from several Best Drug Rehabilitation ...
(Date:7/10/2014)... AURORA, Colo. (July 8, 2014) A new study ... some modest improvements, poor oral health remains a major ... overall. , "The oral health among Native Americans is ... the rest of the country," said Terrence Batliner, DDS, ... Health Research at the School of Public Health. "The ...
(Date:7/10/2014)... 10, 2014 (HealthDay News) -- Adults with dyslexia are ... as children or teenagers than people who don,t have ... Dyslexia, which affects up to 10 percent of ... that 35 percent of adults with this condition said ... 7 percent of those without dyslexia. "Even after ...
(Date:7/10/2014)... Thompson HealthDay Reporter THURSDAY, ... wars that break out regularly between outspoken celebrities or loudmouth ... own relationship, a new study suggests. High amounts of ... if the couple is in a long-term relationship, according to ... In turn, that friction can lead to cheating and breakups, ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:Study finds widespread oral health problems among Navajo 2Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3
... from avian flu, bringing the total number of deaths from ... 27, a Tangerang resident, died late Friday and Jakarta resident ... two and three days of treatment in a hospital here ... flu," said an official at the Indonesian health ministry. ...
... a secret so painful that they even keep it from ... the University of Virginia, the secret exists, //and it’s big. ... high expectations for almost every area of their lives, too ... who is one of the world’s preeminent experts on women’s ...
... graduate student in the Section of Microbial Pathogenesis at ... path taken by Campylobacter// jejuni (campylobacter), as it infects ... the most common causes of diarrhea worldwide, strikes 2.4 ... few unpleasant days, but it can be life threatening ...
... prevailing trend among kids of today, who have turned ... options.// ,Researchers from university of waterloo conducted ... about eating wrong from a tender age. Parents ... which is a leading cause of increasing obesity rates, ...
... knows that a diet laden with fats and sugar, combined ... smoking is a recipe for// major problems including diabetes and ... need to realize that those same bad habits in children ... road. ,The good news: The fix is ...
... findings of a study appearing in the January 2007 issue ... discovered histamine,// the inflammatory compound released during allergic reactions that ... ,They say that histamine can be produced in large amounts ... that is the major component of pus. Pus, a fluid ...
Cached Medicine News:Health News:Women's Sex Lives Mediocre 2Health News:The Uncommon Pathway of Campylobacter Jejuni 2Health News:Cure for Most Heart Attacks Is Free, but It's Important to Start Young 2Health News:Cure for Most Heart Attacks Is Free, but It's Important to Start Young 3Health News:WBC in Lung Produces Histamine: Study 2Health News:WBC in Lung Produces Histamine: Study 3
Foldable Hydrophilic IOL with UV Absorber....
The STAAR ELASTIC LENS®, is a single piece silicone lens to be placed completely in the capsular bag....
... Engineers at Pfizer used wavefront sensing ... Optic Technology. Innovative TECNIS features a patented ... spherical aberration, which compensates for the positive ... result, TECNIS is the first and only ...
... PhacoFlexII SI30NB is foldable silicone ... it's patients. It is used ... SI30NB is indicated for primary ... of aphakia in adults (over ...
Medicine Products: